GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Price-to-Owner-Earnings

Redhill Biopharma (Redhill Biopharma) Price-to-Owner-Earnings : 1.11 (As of Apr. 30, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Price-to-Owner-Earnings?

As of today (2024-04-30), Redhill Biopharma's share price is $0.433. Redhill Biopharma's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.39. It's Price-to-Owner-Earnings for today is 1.11.


The historical rank and industry rank for Redhill Biopharma's Price-to-Owner-Earnings or its related term are showing as below:

RDHL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.08   Med: 1.38   Max: 4.65
Current: 1.12

During the past 13 years, the highest Price-to-Owner-Earnings of Redhill Biopharma was 4.65. The lowest was 0.08. And the median was 1.38.


RDHL's Price-to-Owner-Earnings is ranked better than
99.29% of 421 companies
in the Drug Manufacturers industry
Industry Median: 28.39 vs RDHL: 1.12

As of today (2024-04-30), Redhill Biopharma's share price is $0.433. Redhill Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.81. Therefore, Redhill Biopharma's PE Ratio for today is At Loss.

As of today (2024-04-30), Redhill Biopharma's share price is $0.433. Redhill Biopharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.81. Therefore, Redhill Biopharma's PE Ratio without NRI for today is At Loss.


Redhill Biopharma Price-to-Owner-Earnings Historical Data

The historical data trend for Redhill Biopharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Price-to-Owner-Earnings Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.18 3.12 -

Competitive Comparison of Redhill Biopharma's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Price-to-Owner-Earnings falls into.



Redhill Biopharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Redhill Biopharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.433/0.39
=1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma  (NAS:RDHL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Redhill Biopharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.